CareDx Inc (NASDAQ:CDNA) went up by 0.29% from its latest closing price compared to the recent 1-year high of $99.83. The company’s stock price has collected -4.03% of loss in the last five trading sessions. Press Release reported 17 hours ago that CareDx Expands into the Pre-Transplant Kidney Space through TX Connect
Is It Worth Investing in CareDx Inc (NASDAQ :CDNA) Right Now?
Plus, the 36-month beta value for CDNA is at 0.66. Opinions of the stock are interesting as 5 analysts out of 5 who provided ratings for CareDx Inc declared the stock was a “buy,” while 0 rated the stock as “overweight,” 0 rated it as “hold,” and 0 as “sell.”
The average price from analysts is $98.00, which is $3.57 above the current price. CDNA currently public float of 48.44M and currently shorts hold a 9.47% ratio of that float. Today, the average trading volume of CDNA was 714.64K shares.
CDNA’s Market Performance
CDNA stocks went down by -4.03% for the week, with a monthly jump of 0.38% and a quarterly performance of 33.10%, while its annual performance rate touched 221.02%. The volatility ratio for the week stands at 8.00% while the volatility levels for the past 30 days are set at 6.51% for CareDx Inc. The simple moving average for the period of the last 20 days is -6.25% for CDNA stocks with a simple moving average of 58.07% for the last 200 days.
Analysts’ Opinion of CDNA
Many brokerage firms have already submitted their reports for CDNA stocks, with H.C. Wainwright repeating the rating for CDNA by listing it as a “Buy.” The predicted price for CDNA in the upcoming period, according to H.C. Wainwright is $55 based on the research report published on October 30th of the previous year 2020.
H.C. Wainwright, on the other hand, stated in their research note that they expect to see CDNA reach a price target of $47, previously predicting the price at $45. The rating they have provided for CDNA stocks is “Buy” according to the report published on October 08th, 2020.
H.C. Wainwright gave a rating of “Buy” to CDNA, setting the target price at $45 in the report published on October 02nd of the previous year.
CDNA Trading at -1.50% from the 50-Day Moving Average
After a stumble in the market that brought CDNA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -20.61% of loss for the given period.
Volatility was left at 6.51%, however, over the last 30 days, the volatility rate increased by 8.00%, as shares surge +6.22% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +14.97% upper at present.
During the last 5 trading sessions, CDNA fell by -4.03%, which changed the moving average for the period of 200-days by +163.94% in comparison to the 20-day moving average, which settled at $84.77. In addition, CareDx Inc saw 9.40% in overturn over a single year, with a tendency to cut further gains.
Reports are indicating that there were more than several insider trading activities at CDNA starting from Maag Peter, who sale 10,000 shares at the price of $89.82 back on Feb 05. After this action, Maag Peter now owns 412,800 shares of CareDx Inc, valued at $898,190 using the latest closing price.
SNYDERMAN RALPH, the Director of CareDx Inc, sale 12,000 shares at $88.88 during a trade that took place back on Jan 15, which means that SNYDERMAN RALPH is holding 72,672 shares at $1,066,513 based on the most recent closing price.
Stock Fundamentals for CDNA
Current profitability levels for the company are sitting at:
- -18.83 for the present operating margin
- +63.20 for the gross margin
The net margin for CareDx Inc stands at -17.29. The total capital return value is set at -24.10, while invested capital returns managed to touch -22.50. Equity return is now at value -10.90, with -7.90 for asset returns.
Based on CareDx Inc (CDNA), the company’s capital structure generated 3.33 points at debt to equity in total, while total debt to capital is 3.22. Total debt to assets is 2.08, with long-term debt to equity ratio resting at 0.07. Finally, the long-term debt to capital ratio is 0.07.
When we switch over and look at the enterprise to sales, we see a ratio of 6.88, with the company’s debt to enterprise value settled at 0.00. The receivables turnover for the company is 7.52 and the total asset turnover is 0.87. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.07.